ANZICS CTG Endorsed Study
A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients
A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients. This is a prospective, multicentre study with 7000 patients recruited from 100 sites worldwide, open label randomised controlled trial with blinded outcome assessment.
Jeffrey Lipman (Chair), Stephen Brett, Menino Cotta, Joshua Davis, Jan De Waele, Joel Dulhunty, Simon Finfer, Parisa Glass, Serena Knowles, Shay McGuinness, John Myburgh, David Paterson, Dorrilyn Rajbhandari (Project Manager), Sandra Peake, Andrew Rhodes, Jason Roberts, Charudatt Shirwadkar, Therese Starr, Colman Taylor.
The George Institute for Global Health
University of Queensland
NHMRC – Project Grant – $3,269,942
Project Status as of June 2018
Recruitment has commenced in Australia at pilot site with all sites expected to start imminently. Collaborations have been established with Imperial College, London, UK and University Ziekenhuis, Gent, Belgium to cover European sites.
CTG ID No 1516-04